Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Filamon LTD
AstraZeneca
Merck Sharp & Dohme LLC
Genmab
University of Wisconsin, Madison
Mayo Clinic
BioNTech SE
Aminex Therapeutics, Inc.
Toray Industries, Inc
Dren Bio
STORM Therapeutics LTD
University of Southern California
Merck Sharp & Dohme LLC
Neonc Technologies, Inc.
Hummingbird Bioscience
University of Wisconsin, Madison
Replimune Inc.
Ipsen
Bristol-Myers Squibb
Bristol-Myers Squibb
Children's Oncology Group
Ossium Health, Inc.
Diakonos Oncology Corporation
Duke University
Arvinas Inc.
Immatics US, Inc.
BioInvent International AB
Aulos Bioscience, Inc.
M.D. Anderson Cancer Center
Essen Biotech
Essen Biotech
Sapience Therapeutics
Sanofi
University of California, Davis
Teva Branded Pharmaceutical Products R&D, Inc.
Beijing Tide Pharmaceutical Co., Ltd
IDEAYA Biosciences
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Second Life Therapeutics
Onchilles Pharma Inc
NuCana plc
Ocellaris Pharma, Inc.
Ohio State University Comprehensive Cancer Center
Shanghai JMT-Bio Inc.